Eagle Pharmaceuticals, inc. (EGRX)

[mcsharkey]

Fairly positive investor analysis for EGRX found at THIS LINKFor what it's worth, an excerpt:

Does Eagle Pharmaceuticals Have A Relatively High Or Low P/E For Its Industry?
We can tell from its P/E ratio of 35.99 that there is some investor optimism about Eagle Pharmaceuticals. You can see in the image below that the average P/E (18.6) for companies in the biotechs industry is lower than Eagle Pharmaceuticals's P/E

And includes this graphic

Eagle Pharma has two 8-Ks almost back-to-back, that cause some pondering. Some data here:

Common Stock (EGRX) Institutional Holdings | Nasdaq.
...
Ownership Summary.
Label Value
Institutional Ownership 95.67 %
Total Shares Outstanding (millions) 14
Total Value of Holdings (millions) $751

Link to FORM 8-K March 13, 2020 - On March 13, 2020, the U.S. Court of Appeals for the District of Columbia Circuit affirmed the decision originally issued by the U.S. District Court for the District of Columbia on June 8, 2018 requiring the U.S. Food and Drug Administration to grant Eagle Pharmaceuticals, Inc., or the Company, seven years of orphan drug exclusivity in the U.S. for BENDEKA (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride.


Link to Form 8-K March 17th filed yesterday 2020 Eagle Pharmaceuticals, Inc., or the Company, announced that the Company’s Board of Directors, or the Board, approved a new share repurchase program, or the Share Repurchase Program, providing for the repurchase of up to an aggregate of $160 million of the Company’s outstanding common stock.

I realize this has been a tough year.

GLTUA